Similar articles for PMID: 33443068

Year	Number of Results
1989	1
1996	1
2001	1
2003	2
2004	1
2005	1
2007	1
2008	1
2009	1
2014	1
2015	8
2016	14
2017	22
2018	21
2019	14
2020	14
2021	8

1

⁶⁸Ga-PSMA-11 NDA Approval: A Novel and Successful Academic Partnership.

Carlucci G, Ippisch R, Slavik R, Mishoe A, Blecha J, Zhu S. Carlucci G, et al. J Nucl Med. 2021 Feb;62(2):149-155. doi: 10.2967/jnumed.120.260455. Epub 2020 Dec 18. J Nucl Med. 2021. PMID: 33443068

2

Disparities in PET imaging for prostate cancer at a tertiary academic medical center.

Bucknor MD, Lichtensztajn DY, Lin TK, Borno HT, Gomez SL, Hope TA. Bucknor MD, et al. J Nucl Med. 2020 Sep 25:jnumed.120.251751. doi: 10.2967/jnumed.120.251751. Online ahead of print. J Nucl Med. 2020. PMID: 32978283

3

The Academic NDA: Justification, Process, and Lessons Learned.

Sunderland JJ. Sunderland JJ. J Nucl Med. 2020 Apr;61(4):480-487. doi: 10.2967/jnumed.119.238287. Epub 2020 Feb 7. J Nucl Med. 2020. PMID: 32034112

4

More advantages in detecting bone and soft tissue metastases from prostate cancer using ¹⁸F-PSMA PET/CT.

Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE. Pianou NK, et al. Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7. Hell J Nucl Med. 2019. PMID: 30843003 Free article.

5

Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial.

Fendler WP, Calais J, Eiber M, Flavell RR, Mishoe A, Feng FY, Nguyen HG, Reiter RE, Rettig MB, Okamoto S, Emmett L, Zacho HD, Ilhan H, Wetter A, Rischpler C, Schoder H, Burger IA, Gartmann J, Smith R, Small EJ, Slavik R, Carroll PR, Herrmann K, Czernin J, Hope TA. Fendler WP, et al. JAMA Oncol. 2019 Jun 1;5(6):856-863. doi: 10.1001/jamaoncol.2019.0096. JAMA Oncol. 2019. PMID: 30920593 Free PMC article. Clinical Trial.

6

Randomized prospective phase III trial of ⁶⁸Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT].

Calais J, Czernin J, Fendler WP, Elashoff D, Nickols NG. Calais J, et al. BMC Cancer. 2019 Jan 7;19(1):18. doi: 10.1186/s12885-018-5200-1. BMC Cancer. 2019. PMID: 30616601 Free PMC article.

7

Efaproxiral: GSJ 61, JP 4, KDD 86, RS 4, RSR 13.

[No authors listed] [No authors listed] Drugs R D. 2005;6(3):178-85. doi: 10.2165/00126839-200506030-00007. Drugs R D. 2005. PMID: 15869322 Review.

8

A New Look At United States Drug Development and Approval Times.

DiMasi JA. DiMasi JA. Am J Ther. 1996 Sep;3(9):647-657. doi: 10.1097/00045391-199609000-00008. Am J Ther. 1996. PMID: 11862306

9

Transforming an Academic Radiochemistry Facility for Positron Emission Tomography Drug cGMP Compliance.

Zhu S, Mosessian S, Kroeger K, Sadeghi S, Slavik R, Kinloch S, Moore M, Allen-Auerbach M, Czernin J, Phelps M. Zhu S, et al. Mol Imaging Biol. 2020 Apr;22(2):256-264. doi: 10.1007/s11307-019-01395-6. Mol Imaging Biol. 2020. PMID: 31240531

10

Applications for FDA approval to market a dew drug: patent submission and listing requirements and application of 30-month stays on approval of abbreviated new drug applications certifying that a patent claiming a drug is invalid or will not be infringed. Final rule.

Food and Drug Administration, HHS. Food and Drug Administration, HHS. Fed Regist. 2003 Jun 18;68(117):36675-712. Fed Regist. 2003. PMID: 12814136 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed